Trial Profile
Study of bavituximab in combination with durvalumab in patients with metastatic non-small-cell lung cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2016
Price :
$35
*
At a glance
- Drugs Bavituximab (Primary) ; Durvalumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Jun 2016 New trial record